The Pantheon Awards program, now in its 14th year, brings together more than 600 industry pioneers – including innovators, thought leaders, investors and educators
By: Sara Radcliffe CLSA President & CEO October 26, 2017 Final Call for Tables at CLSA’s 2017 Pantheon Awards On Nov. 10, we will gather with more than 600 professionals from our California life sciences community to celebrate another year of leadership, innovation, and overall excellence at CLSA’s signature event – the 14th … Continue reading CLSA 2018 Industry Report, Event Information, New Members and More!
October 24, 2017 The California Life Sciences Institute has launched a new Innovation Series that will focus on issues most pressing for life science startups from the very early to more advanced stage of development. The inaugural session – Reimbursement 101 – took place on October 24 at Verily in South San Francisco and was sponsored … Continue reading CLSI Launches Innovation Series with Reimbursement Panel at Verily
Heather Shane, Executive Director of the CLSI CARB-X accelerator, spoke at this year’s BIO Investor Forum in San Francisco at a panel on the Antimicrobial Resistance: New Research and Funding Opportunities. The panel sought to explore the growing threat of antimicrobial resistance (AMR), the economic challenges in developing these products, and the incentives proposed … Continue reading CLSI Participates in Antimicrobial Resistance Panel at the 2017 BIO Investor Forum
October 2017 Read the latest in FAST and Fellows news: Current FAST Fall 2017 company Inflammatix, FAST Grads HepaTx (Spring 2017), X-Therma (Spring 2017), Empire Biotechnologies(Fall 2016), SciBac (Fall 2016), Eidos Therapeutics (Spring 2016), and Magnetic Insight (Spring 2015), presented at BIO Investor Forum in San Francisco. FAST Grad Eidos Therapeutics (Spring 2016) initiates Phase … Continue reading FAST & Fellows Round Up
October 2017 Read the latest of CARB-X: CARB-X awarded its 20th project yesterday, funding Amicrobe to develop a new bioengineered antimicrobial designed for direct application to contaminated and infected tissues Read More Powered By CARB-X company Microbiotix and the AMR Centre announce co-development agreement targeting drug resistant P.aeruginosa in critically ill pneumonia patients Read More … Continue reading CARB-X Updates
Despite the best efforts of CLSA and its partner trade associations, both Senate Bill 17 (Hernandez) and Assembly Bill 265 (Wood) reached the Governor’s desk and were signed into law.
More Than One Million Students Access Biology Content Each Month
KitePharma now has the opportunity to offer this therapy through authorized centers across the United States.
Creating a place where companies can translate cutting-edge academic research into commercialized medical treatments and technologies that make it into hospitals and doctors’ offices.